title: Interaction of macrolides with alpha dornase during DNA hydrolysis.
abstract: Since patients with cystic fibrosis are often treated with alpha dornase to reduce sputum viscosity, and because of preliminary reports of efficacy of long-term low-dose erythromycin therapy in chronic airway diseases, it is likely that alpha dornase and macrolides might be given together in such patients. A possible interaction between these drugs was therefore investigated. Using hyperchromic effect to quantify alpha dornase activity, a time- and dose-dependent inhibitory effect on human DNA hydrolysis has been observed for erythromycin, roxithromycin and azithromycin. Inhibitory doses 50% for alpha dornase were graphically determined. Azithromycin exhibited the strongest inhibitory effect.
authors: Laboratoire de Microbiologie, Hôpital Saint-Louis, Paris, France.
authors: L
authors: L
authors: Ripoll
authors: P
authors: P
authors: Reinert
authors: L F
authors: LF
authors: Pépin
authors: P H
authors: PH
authors: Lagrange
mesh_terms: D017963:Azithromycin / Q000494:pharmacology*; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D003850:Deoxyribonuclease I / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D015575:Roxithromycin / Q000494:pharmacology*
chemical_list: D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D015575:Roxithromycin; D004917:Erythromycin; D017963:Azithromycin; D004247:DNA; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I